Redfin Reports November Asking Rents Post Smallest Annual Increase in 15 Months
Rents are growing at half the pace they were in the summer and are expected…
Rents are growing at half the pace they were in the summer and are expected…
The state’s Division of Medicaid and Department of Human Services to deploy Verato’s next-generation healthcare…
The end-to-end solution utilizes Azure digital twin technology to reduce carbon footprint and increase efficiency…
Aetrex will debut its Albert 3DFit foot scanning technology and Foot.com 3D Data Portal for…
New SASE service standard accelerates managed service providers’ ability to offer robust, unified network and…
Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological…
The MEAI-based proprietary compound is aimed at treating Alcohol Use Disorder Tel Aviv, Israel /…
– US board-certified medical oncologist with extensive global clinical and regulatory experience advancing oncology medicines…
GFH009 is First CDK9 Inhibitor Monotherapy to Achieve Compete Response in Acute Myeloid Leukemia Anticancer…
SAB brings extensive expertise in precision oncology, drug development, and early phase clinical trials NEW…
Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All…
Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer Steven Tuch, Chief Financial Officer…
YONKERS, N.Y., Dec. 13, 2022 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
Patients treated in dose-escalation portion of Phase 1/2 study evaluating seclidemstat in combination with azacitidine…
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals,…
MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
In December 2022, the 15th patient was dosed with IMX-110 IMX-110 clinical trial data expected…
Significant single-agent activity in diffuse large B-cell lymphoma (DLBCL) cell models and in mouse model…
Agency assigns PDUFA action date of May 8, 2023 MydCombi™, if approved, would be the…
Additional analyses of non-small cell lung cancer (NSCLC) studies support the efficacy of plinabulin monotherapy…